Evidence of Artemisinin-Resistant Malaria in Africa

1. World malaria report 2020. Geneva: World Health Organization, 2020.

2. Bhatt S, Weiss DJ, Cameron E, et al. The effect of malaria control on Plasmodium falciparum in Africa between 2000 and 2015. Nature 2015;526:207-211.

3. Ashley EA, Dhorda M, Fairhurst RM, et al. Spread of artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2014;371:411-423.

4. Noedl H, Socheat D, Satimai W. Artemisinin-resistant malaria in Asia. N Engl J Med 2009;361:540-541.

5. Dondorp AM, Nosten F, Yi P, et al. Artemisinin resistance in Plasmodium falciparum malaria. N Engl J Med 2009;361:455-467.

6. WWARN K13 Genotype-Phenotype Study Group. Association of mutations in the Plasmodium falciparum Kelch13 gene (Pf3D7_1343700) with parasite clearance rates after artemisinin-based treatments — a WWARN individual patient data meta-analysis. BMC Med 2019;17:1-1.

7. Amaratunga C, Sreng S, Suon S, et al. Artemisinin-resistant Plasmodium falciparum in Pursat province, western Cambodia: a parasite clearance rate study. Lancet Infect Dis 2012;12:851-858.

8. Report on antimalarial drug efficacy, resistance and response: 10 years of surveillance (2010–2019). Geneva: World Health Organization, November 2020.

9. Kayiba NK, Yobi DM, Tshibangu-Kabamba E, et al. Spatial and molecular mapping of Pfkelch13 gene polymorphism in Africa in the era of emerging Plasmodium falciparum resistance to artemisinin: a systematic review. Lancet Infect Dis 2021;21(4):e82-e92.

10. Uwimana A, Umulisa N, Venkatesan M, et al. Association of Plasmodium falciparum kelch13 R561H genotypes with delayed parasite clearance in Rwanda: an open-label, single-arm, multicentre, therapeutic efficacy study. Lancet Infect Dis 2021 April 14 (Epub ahead of print).

11. Ikeda M, Kaneko M, Tachibana S-I, et al. Artemisinin-resistant Plasmodium falciparum with high survival rates, Uganda, 2014-2016. Emerg Infect Dis 2018;24:718-726.

12. Asua V, Vinden J, Conrad MD, et al. Changing molecular markers of antimalarial drug sensitivity across Uganda. Antimicrob Agents Chemother 2019;63(3):e01818-18-e01818-18.

13. Asua V, Conrad MD, Aydemir O, et al. Changing prevalence of potential mediators of aminoquinoline, antifolate, and artemisinin resistance across Uganda. J Infect Dis 2021;223:985-994.

14. White LJ, Flegg JA, Phyo AP, et al. Defining the in vivo phenotype of artemisinin-resistant falciparum malaria: a modelling approach. PLoS Med 2015;12(4):e1001823-e1001823.

15. White NJ. Malaria parasite clearance. Malar J 2017;16:88-88.

16. Balikagala B, Mita T, Ikeda M, et al. Absence of in vivo selection for K13 mutations after artemether-lumefantrine treatment in Uganda. Malar J 2017;16:23-23.

17. Yeka A, Gasasira A, Mpimbaza A, et al. Malaria in Uganda: challenges to control on the long road to elimination: I. Epidemiology and current control efforts. Acta Trop 2012;121:184-195.

18. Kigozi SP, Kigozi RN, Sebuguzi CM, et al. Spatial-temporal patterns of malaria incidence in Uganda using HMIS data from 2015 to 2019. BMC Public Health 2020;20:1913-1913.

19. National Malaria Control Division. National malaria annual report 2017-2018. Kampala, Uganda: Ministry of Health, 2019.

20. Guidelines for the treatment of malaria. 3rd ed. Geneva: World Health Organization, April 2015.

21. Flegg JA, Guerin PJ, White NJ, Stepniewska K. Standardizing the measurement of parasite clearance in falciparum malaria: the parasite clearance estimator. Malar J 2011;10:339-339.

22. Witkowski B, Amaratunga C, Khim N, et al. Novel phenotypic assays for the detection of artemisinin-resistant Plasmodium falciparum malaria in Cambodia: in-vitro and ex-vivo drug-response studies. Lancet Infect Dis 2013;13:1043-1049.

23. Ariey F, Witkowski B, Amaratunga C, et al. A molecular marker of artemisinin-resistant Plasmodium falciparum malaria. Nature 2014;505:50-55.

24. Miotto O, Amato R, Ashley EA, et al. Genetic architecture of artemisinin-resistant Plasmodium falciparum. Nat Genet 2015;47:226-234.

25. Miotto O, Sekihara M, Tachibana S-I, et al. Emergence of artemisinin-resistant Plasmodium falciparum with kelch13 C580Y mutations on the island of New Guinea. PLoS Pathog 2020;16(12):e1009133-e1009133.

26. Talundzic E, Okoth SA, Congpuong K, et al. Selection and spread of artemisinin-resistant alleles in Thailand prior to the global artemisinin resistance containment campaign. PLoS Pathog 2015;11(4):e1004789-e1004789.

27. Ihaka R, Gentleman R. R: a language for data analysis and graphics. J Comput Graph Stat 1996;5:299-314.

28. Hawkes M, Conroy AL, Opoka RO, et al. Slow clearance of Plasmodium falciparum in severe pediatric malaria, Uganda, 2011-2013. Emerg Infect Dis 2015;21:1237-1239.

29. Lu F, Culleton R, Zhang M, et al. Emergence of indigenous artemisinin-resistant Plasmodium falciparum in Africa. N Engl J Med 2017;376:991-993.

30. Conrad MD, Rosenthal PJ. Antimalarial drug resistance in Africa: the calm before the storm? Lancet Infect Dis 2019;19(10):e338-e351.

31. Huang F, Takala-Harrison S, Jacob CG, et al. A single mutation in K13 predominates in southern China and is associated with delayed clearance of Plasmodium falciparum following artemisinin treatment. J Infect Dis 2015;212:1629-1635.

32. Siddiqui FA, Boonhok R, Cabrera M, et al. Role of Plasmodium falciparum Kelch 13 protein mutations in P. falciparum populations from northeastern Myanmar in mediating artemisinin resistance. mBio 2020;11(1):e01134-19-e01134-19.

33. Uwimana A, Legrand E, Stokes BH, et al. Emergence and clonal expansion of in vitro artemisinin-resistant Plasmodium falciparum kelch13 R561H mutant parasites in Rwanda. Nat Med 2020;26:1602-1608.

34. MalariaGEN Plasmodium falciparum Community Project. Genomic epidemiology of artemisinin resistant malaria. Elife 2016;5:e08714-e08714.

35. McCallum FJ, Persson KE, Mugyenyi CK, et al. Acquisition of growth-inhibitory antibodies against blood-stage Plasmodium falciparum. PLoS One 2008;3(10):e3571-e3571.

36. Sabchareon A, Burnouf T, Ouattara D, et al. Parasitologic and clinical human response to immunoglobulin administration in falciparum malaria. Am J Trop Med Hyg 1991;45:297-308.

37. Lee SA, Yeka A, Nsobya SL, et al. Complexity of Plasmodium falciparum infections and antimalarial drug efficacy at 7 sites in Uganda. J Infect Dis 2006;193:1160-1163.

38. ACTwatch Group and PACE. ACTwatch study reference document: the Republic of Uganda Outlet Survey 2015. Washington, DC: Population Services International, 2015 (http://www.actwatch.info/sites/default/files/content/publications/attachments/Uganda%202015%20OS%20Report.pdf).

39. Clinton Health Access Initiative, UNITAID. Injectable artesunate assessment report. Geneva: Severe Malaria Observatory, 2019.

40. van der Pluijm RW, Imwong M, Chau NH, et al. Determinants of dihydroartemisinin-piperaquine treatment failure in Plasmodium falciparum malaria in Cambodia, Thailand, and Vietnam: a prospective clinical, pharmacological, and genetic study. Lancet Infect Dis 2019;19:952-961.

留言 (0)

沒有登入
gif